The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer

Published:2017-05-26 Issue:1 Volume:4 Page:47-58
ISSN:2212-697X
Container-title:Clinical Cancer Drugs
language:en
Short-container-title:CCAND

Author:

Hahne Jens C.,Engel Jorg B.,Honig Arnd,Meyer Susanne R.,Zito Domenico,Lampis Andrea,Valeri Nicola

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,General Pharmacology, Toxicology and Pharmaceutics,Oncology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma;Current Molecular Pharmacology;2021-12-16

2. Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer;Current Cancer Drug Targets;2020-09-04

3. Neogambogic acid induces apoptosis of melanoma B16 cells via the PI3K/Akt/mTOR signaling pathway;Acta Biochimica Polonica;2020-06-19

4. Cytotoxicity of new pyridazin-3(2H)-one derivatives orchestrating oxidative stress in human triple-negative breast cancer (MDA-MB-468);Archiv der Pharmazie;2018-10-29

5. Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumor Agents via an Immunofluorescence and EdU Labeling Strategy;Frontiers in Pharmacology;2018-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP